ArticleNeuroimmunomodulation2026
Taselisib, a PI3K Inhibitor, Alleviates Neuropathic Pain through HIF-1α-Mediated Angiogenesis in a Rat Model of Chronic Constriction Injury.
Article in Neuroimmunomodulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeuropathic pain is associated with hypoxia, inflammation, and metabolic dysregulation, in which hypoxia-inducible factor-1α (HIF-1α) plays a key regulatory role. This study investigates whether phosphoinositide 3-kinase (PI3K) inhibition by taselisib alleviates neuropathic pain via suppression of HIF-1α-mediated pathological signaling.
methodsIn this study, a rat model of chronic constriction injury (CCI) was used to investigate whether neuropathic pain could be alleviated by taselisib, a selective PI3K inhibitor. Taselisib was administered daily, with or without co-administration of dimethyloxalylglycine (DMOG), a HIF-1α activator. Mechanical allodynia and thermal hyperalgesia were evaluated using behavioral tests. mRNA level in the dorsal root ganglia (DRG) was quantified by RT-qPCR, whereas protein levels were assessed by Western blotting, immunofluorescence, and metabolic assays were performed to assess angiogenesis, glycolytic activity, and inflammatory responses.
resultsTaselisib significantly alleviated mechanical allodynia and thermal hyperalgesia in CCI rats, effects that were attenuated by co-administration of the HIF-1α activator DMOG. Taselisib suppressed CCI-induced upregulation of HIF-1α in DRG at both transcript and protein levels, and this suppression was reversed by DMOG. Downstream targets of HIF-1α, including mTOR, VEGFA, GLUT1, PFKM, and PDK1, were similarly downregulated by taselisib and partially restored upon HIF-1α activation. Metabolically, taselisib reduced lactate accumulation and restored ATP levels, indicating inhibition of glycolytic reprogramming. Taselisib also attenuated systemic and DRG-localized inflammatory responses, including IL-6, IL-1β, and NF-κB p65 expression; these anti-inflammatory effects were mitigated by DMOG.
conclusionTaselisib alleviates neuropathic pain by disrupting HIF-1α-mediated angiogenic, inflammatory, and metabolic signaling. Targeting the PI3K-HIF-1α axis offers a promising therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.